AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05363189 — intervention group
Intervention type: PROCEDURE
Intervention: Venous augmentation
Description: Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
Study NCT05363189 — intervention group
Intervention type: PROCEDURE
Intervention: Traditional ERAS (enhanced recovery after surgery) protocol
Description: Pre-, peri-, and post-operative care as described in the ERAS protocol
Study NCT05363189 — intervention group
Intervention type: PROCEDURE
Intervention: Sahlgrenska recovery protocol
Description: Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
Study NCT05363189 — intervention group
Intervention type: PROCEDURE
Intervention: No venous augmentation
Description: Traditional deep inferior epigastric artery perforator flap (DIEP)
Study NCT05396144 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nitrous oxide
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Study NCT05396144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Study NCT05590507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Audio Recordings
Description: A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
Study NCT05233436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously
Study NCT04947332 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auto-inoculation
Description: A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
Study NCT06337812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Starch
Description: Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study.
Study NCT05655949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT05655949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion
Study NCT05655949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion
Study NCT05655949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90
Description: Injection of radiation microsphere beads
Study NCT06327828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)
Description: Semi-automated computer-aided treatment based on a mathematical model
Study NCT06327828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Guiding methimazole therapy based on the treating physician's decision
Study NCT05954000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Behavioral Change Techniques
Description: 1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT04713956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study NCT06407245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Snacks
Description: The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application.
Study NCT05422001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose ketamine
Description: Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml
Study NCT06407245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Exercise
Description: The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application.
Study NCT03607955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is supplied by Aravive Biologics
Study NCT03607955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available
Study NCT03607955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Commercially available
Study NCT03607955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue from Diagnostic Laparoscopy
Description: -For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
Study NCT03607955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue from Core biopsy
Description: -Standard of care procedure but research specimens will be collected
Study NCT05422001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Isotonic Saline
Study NCT03607955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval Debulking
Description: * Standard of Care~* Research tissue samples will be collected
Study NCT03607955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
Study NCT03607955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites collection
Description: -A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
Study NCT05031052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End-ischemic normothermic oxygenated machine perfusion
Description: Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
Study NCT05031052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static cold storage
Description: Immediate implantation of kidney allograft after conventional and static preservation on ice
Study NCT06448624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin sulbactam 3 days
Description: Ampicillin sulbactam 1.5 gram IV TID for 3 days after CIED implantation
Study NCT06448624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3 days
Description: Placebo for 3 days after CIED implantation
Study NCT04966949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral prostate capsule sparing or neurovascular bundles sparing
Description: When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
Study NCT04966949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral prostate capsule sparing or neurovascular bundles sparing
Description: When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
Study NCT06082856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
Study NCT06082856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
Study NCT05791227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sonographer Evaluation
Description: A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
Study NCT05791227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI Evaluation
Description: An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
Study NCT06267612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of left ventricular assist device for hemodynamic support
Study NCT06009055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3mg/kg，injection completed in 30 seconds
Study NCT06009055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg/kg，injection completed in 30 seconds
Study NCT04957121 — intervention group
Intervention type: OTHER
Intervention: on-hours
Description: If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours.
Study NCT04957121 — intervention group
Intervention type: OTHER
Intervention: off-hours
Description: If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours.
Study NCT06457711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Free diet Group (FDG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
Study NCT06457711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low Calorie Ketogenic Diet Group (VLCKDG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
Study NCT06457711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting Group (IFG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
Study NCT04875052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Whole Body Vibration
Description: Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
Study NCT04875052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Local Muscle Vibration
Description: Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
Study NCT04875052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL Rehabilitation
Description: Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
Study NCT06409247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iExposure
Description: There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
Study NCT06409247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iExposure plus attention guidance
Description: The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
Study NCT06409247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iExposure plus attention control
Description: The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
Study NCT04952220 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
Study NCT05409235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTT166
Description: Participants will receive OTT166 ophthalmic solution
Study NCT05409235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Participants will receive vehicle control
Study NCT05090761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB
Study NCT05090761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
Study NCT05090761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
Study NCT04906642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science
Description: Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
Study NCT04906642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Normal Saline will be used in place of Next Science for irrigation
Study NCT05339607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal ablation of resection margins by STSC and biliary orifice by cystotome.
Description: Patients who are eligible will undergo thermal ablation of the resection margins.
Study NCT05024747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm CQ patch (GSK Dungarvan)
Description: A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
Study NCT05024747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm CQ (Alza)
Description: A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
Study NCT06409273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid course on medical thesis for post graduates general practice students
Description: Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.
Study NCT06409273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face teaching on medical thesis for post graduates general practice students
Description: Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.
Study NCT04908592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
Study NCT04908592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
Study NCT06058013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study NCT06058013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study NCT04982289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.
Study NCT04982289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an SC infusion.
Study NCT05519748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducational program
Description: The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
Study NCT05519748 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online psychoeducational program
Description: The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
Study NCT06472934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in the absence of B-blocker treatment
Description: Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.
Study NCT06472934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
Study NCT05819775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
Study NCT06056505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial kidney nephrectomy
Description: surgery for partial nephrectomy
Study NCT04935476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 85 mg PO BID
Description: Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.